Physician profile
Mariah Shultz
NPI 1538728613
$2,353.34
in general payments reported to CMS, 2019-2025
21 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.94 · 2022: $18.03 · 2023: $529 · 2024: $668 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.38 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.34 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $341.11 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $314.85 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $208.04 | 2023-2025 | Auvelity, Sunosi |
| Indivior INC. | $164.88 | 2023-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $162.75 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Corium, LLC | $124.62 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $108.48 | 2024-2025 | Spravato, Invega Sustenna |
| Almatica Pharma LLC | $102.90 | 2023-2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $101.12 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $69.94 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.36 | 2023-2025 | Caplyta |
| Hikma Pharmaceuticals USA | $42.00 | 2023 | Kloxxado |
| Neurocrine Biosciences, INC. | $36.72 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $30.58 | 2023-2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.34 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.83 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.85 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2025 | Trintellix |
| Tris Pharma INC | $14.55 | 2023 | Dyanavel Xr |
| Cumberland Pharmaceuticals, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.